Effects of lead on polymorphonuclear leukocyte (PMN) functions in occupationally exposed workers.
Previous in vitro experiments have shown that lead can inhibit PMN chemotaxis, phagocytosis and superoxide formation. Moreover, we have observed an inhibition of PMN chemotaxis in workers occupationally exposed to lead with a mean blood lead concentration of 3.06 mumol/l. The present study was carried out to evaluate locomotion and luminol assisted chemiluminescence (CL) of polymorphonuclear leukocytes (PMN) harvested from ten lead occupationally exposed workers with blood lead concentrations of 1.59 mumol/l (SD 0.27 mumol/l). Since lipids affect PMN activity and lipid composition is modified in erythrocytes of lead workers, PMN lipids were also studied. Ten healthy male subjects of the same age were taken as controls. Chemotaxis, i.e. locomotion stimulated through a specific membrane receptor, was impaired in the PMN of lead workers, but random migration, i.e. unstimulated cell locomotion, and respiratory burst were both unmodified. Cholesterol and phospholipids were not changed, but the percentage of arachidonic acid was significantly increased. The release of LTB4, generated by the oxidative metabolism of arachidonic acid, was increased. CL, which detects reactive oxygen species (ROS), was unmodified, but this lack of change could be the result of an increase in ROS, due to the augmentated percentage of arachidonic acid, and of a decrease in ROS, due to a direct inhibitory effect of lead on ROS generation. On the basis of the results from these ex vivo experiments, the conclusion that chemotaxis is the PMN function primarily affected by lead was confirmed. PMN are considered to be one of the first cellular targets for the action of lead; low exposure to lead modifies their activity and mainly modifies chemotaxis and LTB4 production.
Valentino
M
M
Institute of Occupational Medicine, University of Ancona, Italy.
Governa
M
M
Marchiseppe
I
I
Visonă
I
I
D000328:Adult; D002634:Chemotaxis, Leukocyte / Q000187:drug effects; D002784:Cholesterol / Q000097:blood; D006801:Humans; D007854:Lead / Q000097:blood / Q000633:toxicity*; D007975:Leukotriene B4 / Q000096:biosynthesis; D008875:Middle Aged; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D009504:Neutrophils / Q000187:drug effects* / Q000502:physiology; D016273:Occupational Exposure; D010743:Phospholipids / Q000097:blood
D010743:Phospholipids; D007975:Leukotriene B4; D007854:Lead; D009240:N-Formylmethionine Leucyl-Phenylalanine; D002784:Cholesterol